Involvement of leukotriene pathway in the pathogenesis of ischemia-reperfusion injury and septic and non-septic shock. by ROSSI A et al.
 Current Vascular Pharmacology, 2009, 7, 000-000 1 
 1570-1611/09 $55.00+.00 © 2009 Bentham Science Publishers Ltd. 
Involvement of Leukotriene Pathway in the Pathogenesis of Ischemia-
Reperfusion Injury and Septic and Non Septic Shock 
Antonietta Rossi
1
, Salvatore Cuzzocrea
1,2,* 
and
 
Lidia Sautebin
3,*
 
1
IRCCS Centro Neurolesi “Bonino-Pulejo”, Via Provinciale Palermo C. Da Casazza, 98124 Messina, Italy; 
2
Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Via C. Valeria, 5-98125 
Messina, Italy; 
3
Department of Experimental Pharmacology, University of Naples Federico II, Via D. Montesano, 49-
80131 Naples, Italy 
Abstract: The 5-lipoxygenase (5-LO) pathway is responsible for the production of leukotrienes (LTs), inflammatory lipid 
mediators which play a role in innate immunity. More recently, a pivotal role of LTs in ischemia-reperfusion and shock 
injury has been suggested. Infact, these pathological conditions are characterized by a severe neutrophil infiltration that 
gives rise to tissue injury and 5-LO metabolites control neutrophil recruitment in injured tissue by the modulation of adhe-
sion molecule expression. The aim of this review is to analyze the results reported in the literature on the role of 5-LO 
pathway, with particular regard to LTs, in these pathological conditions. A better understanding of the mechanisms under-
lying the role of the 5-LO enzyme and/or its metabolites in the regulation of neutrophil trafficking, might open new per-
spectives in the therapy of organ dysfunction and/or injury associated with shock and ischemia-reperfusion injury.  
Keywords: 5-lipoxygenase, adhesion molecules, ischemia-reperfusion injury, leukotrienes, neutrophil infiltration, septic shock, 
non-septic shock.  
1. LEUKOTRIENES 
1.1. Leukotriene Biosynthesis 
 Leukotrienes (LTs) (“leuko” from white blood cells and 
“trienes” three conjugated double bonds) are products of the 
5-lipoxygenase (5-LO) pathway. The biosynthetic pathway 
of LTs initiates with the migration of 5-LO and cytosolic 
phospholipase A2 (cPLA2) to the nucleus, where cPLA2 lib-
erates arachidonic acid AA from phospholipids, which is 
then transferred by an integral membrane protein 5-
lipoxygenase-activating protein (FLAP) to 5-LO. For full 
activity 5-LO requires cofactors (calcium and ATP) and in-
teraction with other proteins besides FLAP, such as the coac-
tosin-like protein (CLP), which stimulates 5-LO activity and 
colocalizes with the enzyme [1]. The production of LTs be-
gins with the insertion by 5-LO of molecular O2 at carbon-5 
of AA to produce 5-hydroperoxyeicosatetraenoic acid (5-
HPETE). Five-HPETE can be reduced to 5-hydroxyeico-
satetraenoic acid (5-HETE), which can be in turn dehydro-
genated to 5-oxo-ETE. Moreover, 5-LO catalyzes a second 
enzymatic step, the conversion of 5-HPETE to leukotriene 
A4 (LTA4), an unstable intermediate [2] that can be catalyti-
cally converted to leukotriene B4 (LTB4) by LTA4 hydrolase 
[3] or can be conjugated with reduced glutathione by leukot-
riene C4 (LTC4) synthase (LTC4S). LTB4 and LTC4 are ex-
ported from the cell by specific transporter proteins. 
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The LTC4 is subjected to extracellular cleavage of the glu-
tamic acid (through a -glutamyl transpeptidase) and subse-
quently of the glycine moiety (through a dipeptidase), to 
provide respectively leukotriene D4 (LTD4) and E4 (LTE4) 
[4].  
 Interestingly, it has been demonstrated that there are alle-
lic variants of the coding and promoter regions of the genes 
encoding for the enzymes involved in LT biosynthesis, such 
as 5-LO [5], FLAP [6], LTA4 hydrolase [7] and LTC4S [8]. 
 The LT synthesis is regulated by different mechanisms 
involving: a) the amount of free arachidonate released by 
PLA2 from cell-membrane phospholipids, [9, 10], b) the 
availability of small molecules (e.g. ATP), c) the level and 
the catalytic activity of each of the proteins involved in the 
5-LO pathway, and, d) the 5-LO post-translational modifica-
tions [e.g. phosphorylation by p38 kinase-dependent mito-
gen-activated protein kinase (MAPK) [11], phosphorylation 
on Ser 663 by extracellular signal-regulated kinase (ERK)] 
[12]. Another variable that influences LT synthesis is the 
intracellular localization of 5-LO. In resting cells, 5-LO oc-
curs as a soluble enzyme either in the cytosol or in the nu-
cleus, depending on the cell type [12]. In neutrophils, cyto-
plasmic 5-LO associates with the endoplasmatic reticulum 
and with the outer nuclear membrane, whereas in dendritic 
cells or in alveolar macrophages has an intranuclear localiza-
tion that seems to be correlated with a higher capacity for LT 
generation [13]. Cell stimulation by various agonists causes 
5-LO translocation from soluble compartments to the nuclear 
membrane and the consequent LT generation. LTs are pre-
dominantly synthesized by inflammatory cells like polymor-
phonuclear leukocytes (PMNs), monocytes, macrophages, 
mast cells and dendritic cells [for review see 14]. Although 
non leukocyte cells (like endothelial cells) generally do not 
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have sufficient 5-LO and FLAP to synthesize appreciable 
amounts of LTs, such cells expressing only LTA4-
metabolizing enzymes can take up leukocyte-derived LTA4 
and metabolize it into bioactive LTs, a process that is termed 
“transcellular biosynthesis”[15].  
1.2. Leukotriene Receptors and Biological Effects 
 LTs exert their actions through seven-transmembrane G 
protein coupled receptors consisting of 2 subclasses: recep-
tors activated by LTB4 (BLT receptors) and cysteinyl LT 
(cysLT) receptors, activated by the cysLTs (LTC4, LTD4 and 
LTE4) [16].  
 These receptors, after binding to LTs, interact with G 
proteins, thereby eliciting increases in intracellular calcium 
and reductions in intracellular cyclic AMP [for review see 
14]. These proximal signals activate downstream kinase cas-
cades in ways that alter various cellular activities, ranging 
from motility to transcriptional activation.  
 The BLT receptors are denoted BLT1 and BLT2, based on 
their affinity for the agonist [17]. In particular, LTB4 acting 
through BLT1 can cause chemotaxis, degranulation, adhesion 
and an enhancement of the neutrophil survival. Although 
BLT1 was long known to be a neutrophil chemoattractant 
receptor, recent studies identified BLT1 expression in 
macrophages, smooth muscle cells, endothelial cells, acti-
vated T-cells, mast cells, eosinophils and basophils [for re-
view see 14]. Functional expression of BLT1 on both mature 
and immature dendritic cells has been recently demonstrated 
supporting a direct effect of LTB4 in the control of adaptive 
immune responses [18]. The use of knockout (KO) mice for 
BLT1, generated in several laboratories, have been funda-
mental in defining a critical role for this receptor in diverse 
inflammatory diseases, such as atherosclerosis [19], asthma, 
autoimmune uveitis and arthritis [for review see 20]. In con-
trast, the function and biological activities of BLT2 are com-
pletely unknown, although this receptor is expressed on neu-
trophils, macrophages, T lymphocyte, mast cells, B lympho-
cyte, eosinophils, dendritic cells and hematopoietic progeni-
tor cells [for review see 14]. Moreover, this receptor has 
been shown to be expressed widely in humans being with the 
highest expression in spleen and peripheral blood leukocytes 
[21]. However, varying results has been reported as regard to 
murine BLT2 expression [22-24]. Recently, it has been re-
ported that BLT2 expression portends worse clinical parame-
ters for ovarian cancer [25].  
 The receptors activated by the cysLTs are referred to as 
CysLT1 and CysLT2 [26]. CysLT1, [27] mediates sustained 
bronchoconstriction, mucus secretion, and edema in the air-
ways. Selective antagonists of CysLT1, that are approved for 
the treatment of asthma, block the proasthmatic effects of 
CysLT1 stimulation. Experiments in mice that are deficient 
in CysLT2 [28] or that overexpress CysLT2 in the lungs [29] 
indicate that CysLT2 does not mediate bronchoconstriction 
but, rather, contributes to inflammation, vascular permeabil-
ity and tissue fibrosis. There are no known specific antago-
nists of CysLT2. Interestingly, certain reported actions of 
cysLTs are not readily explained by either CysLT1 or 
CysLT2, raising the possibility of the presence of CysLT1–
CysLT2 heterodimers or additional receptors [30]. One can-
didate is G protein –coupled receptor 17 (GPR17), a dual-
uracil nucleotide–cysLT receptor [31].  
1.3. Leukotrienes and Diseases 
 LTs play an integral role in the pathophysiology of 
asthma. In fact, the role of LTs in this disease has been vali-
dated in clinical trials of anti-LT agents. In particular, the 
anti-LT therapy (zileuton, a 5-LO inhibitor [32], and monte-
lukast or zafirlukast [33, 34], CysLT1 antagonists) improve 
pulmonary function, decreases daytime and nocturnal bron-
choconstriction episodes and increases quality of life in chil-
dren and adults with asthma. Recently, it has been demon-
strated that anti-LT agents exert beneficial effects on other 
diseases commonly associated with asthma (exercise induced 
asthma, rhinitis, chronic obstructive pulmonary disease, in-
terstitial lung disease, chronic urticaria, atopic dermatitis, 
allergic fungal disease, nasal polyposis, and paranasal sinus 
disease) as well as on diseases not connected to asthma [35]. 
In fact, the overproduction of LTs has been also associated 
with atherosclerosis [36, 37], hyperlipidemia-dependent in-
flammation of the arterial wall [38], pulmonary hypertension 
[39], arthritis (including osteoarthritis and gout) [40], glome-
rulonephritis, interstitial cystitis and psoriasis [14]. In addi-
tion, increased 5-LO expression, and presumably increased 
LT synthesis, has been associated with several tumour types 
such as lung [41], pancreatic [42], bladder [43], breast [44], 
colon [45], multiforme glioblastoma [46], prostate [47], tes-
ticular [48] and esophageal cancer [49]. The role of LTs in 
carcinogenesis seems to be related to their action on funda-
mental cellular processes such as differentiation and prolif-
eration through the transcription of various cytokines and 
growth factors [50]. Recently, we have demonstrated by the 
use of 5-LOKO mice, 5-LO inhibitor and CysLT1 receptor 
antagonist, that LTs are important mediators of several 
pathological conditions characterized by an excessive neu-
trophil activation (pleurisy [51], acute pancreatitis [52], coli-
tis [53, 54], spinal cord injury [55], septic and non septic 
shock [56, 57] and ischemia/reperfusion injury [58, 59]) by 
promoting neutrophil migration through an up-regulation of 
adhesion molecule expression. 
2. INVOLVEMENT OF LEUKOTRIENES IN THE 
PATHOGENESIS OF ISCHEMIA-REPERFUSION 
INJURY 
2.1. Ischemia-Reperfusion Injury 
 Ischemia and reperfusion (I/R) injury, that develops 
when blood flow is interrupted for a long period of time and 
then restarts, occurs in a wide range of situations, including 
trauma, vascular reflow after contraction, transluminal coro-
nary angioplasty, thrombolysis treatment, organ transplanta-
tion and hypovolemic shock with resuscitation. When a tis-
sue is subjected to ischemia, a sequence of chemical reac-
tions is initiated that may ultimately lead to cellular dysfunc-
tion and necrosis. In fact, if the ischemia is severe enough, 
the rate of metabolism is diminished and the generation of 
high energy compounds subsequently declines (e.g. ATP). 
The reduced energy metabolism eventually leads to a slow 
but significant degree of tissue injury and necrosis. This de-
gree of tissue injury is further enhanced and accelerated by 
reperfusion that leads to reoxygenation and to the formation 
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and activation of a variety of humoral mediators of injury 
and inflammation. Another key factor of reperfusion injury is 
PMN activation and infiltration in the ischemic area. Multi-
ple studies identified consecutive stages of PMN activation 
and substances being involved in it [60]. It has become ap-
parent that PMN infiltration is not, as once thought, a secon-
dary phenomenon following ischemia. Rather, PMNs are 
active participants in the pathophysiology of infarction, ex-
acerbating the tissue damage [61]. In fact, they produce sev-
eral toxic mediators including oxygen derived free radicals 
(e. g. superoxide radicals, hydroxyl radicals, hydrogen per-
oxide) and lipid mediators (e.g. platelet activating polypep-
tide mediators factor as well as LTs). Main interest lies in 
cellular adhesion molecules, particularly selectins and in-
tegrins, as their antagonists were repeatedly found to dimin-
ish neutrophil activation and infarct size [60].  
2.2. Leukotrienes and Cerebral I/R Injury 
 Transient cerebral ischemia initiates a complex series of 
metabolic events which ultimately lead to neuronal death. 
After cerebral ischemia, the highly complex pathophysi-
ological process that follows can be separated into 3 succes-
sive phases: metabolic stress and excitotoxicity (acute, 
within hours), inflammation and apoptosis (subacute, hours 
to days), and repair and regeneration (chronic, days to 
months)[62, 63]. Post-ischemic inflammation in the subacute 
phase is an important event in which a large number of cells 
and molecules/mediators are involved. Among the inflamma-
tory cells, the accumulation of neutrophils and macro-
phage/microglia in the brain is determinant in the cerebral 
I/R pathogenesis [64-66].  
 The importance of LTs in cerebral I/R has been proven 
by several authors [67-70] who demonstrated that 5-LO ex-
pression as well as LT levels are elevated in ischemic brain 
[71-74]. In particular, in a gerbil model of transient fore-
brain, it has been reported that, during reperfusion, neurons 
exhibit dense 5-LO immunoreactivity and the enzyme is re-
distributed from cytosol to particulate fraction after 3 min 
reperfusion. Moreover, an increase in LTC4 levels in all 
forebrain regions during reperfusion has been observed, al-
though post-ischemic increase was inhomogeneous. In fact, 
the increase in the hippocampus was greater than in cerebral 
cortex. Thus, it has been suggested that reperfusion, which 
was associated with translocation of cytosolic 5-LO to mem-
branes, induced the biosynthesis of LTC4 that may mediate 
irreversible reperfusion injury in the hippocampal neurons 
[71]. An increase in cysLT production has been also ob-
served in rats [68]. In fact, it has been demonstrated in the 
brain of the rats with focal cerebral ischemia an increase of 
cysLT production with 2 peaks at 3–24 h and 7 days after 
middle cerebral artery occlusion and reperfusion. In the late 
phase (7-14 days) [68] the increased cysLTs are tempo-
spatially related to the astrocytosis in the penumbral region 
[68]. Other experimental evidences suggest that astrocytes, 
the predominant cell type in the brain, are affected and con-
tribute to the cerebral ischemic injury [75] through the pro-
duction of LTs. In fact, it has been reported that the cultured 
astrocytes produced cysLTs after 1h oxygen-glucose depri-
vation (OGD)-induced in vitro ischemia. Moreover, it has 
been hypothesized that the released cysLTs might play an 
autocrine role in the induction of reactive astrocytosis 
through the interaction with CysLT1 receptor [76]. In par-
ticular, in vitro ischemia activates astrocytes to produce 
cysLTs that result in CysLT1 receptor-mediated proliferation 
and CysLT2 receptor-mediated death [77].  
 The CysLT receptors, CysLT1 and CysLT2, seem to be 
the also responsible for the increased blood–brain barrier 
permeability and for the induced brain edema and neutrophil 
infiltration observed after cerebral ischemia [72, 78-80]. In 
fact, CysLT1 receptor mRNA has been detected in the brain 
[81] and its protein has been found to be primarily expressed 
in the microvascular endothelium of the human brain tissue 
[82]. An increase in the expression, spatio-temporally related 
to acute neuronal injury and late astrocyte proliferation, was 
also observed in rat brain after focal cerebral ischemia. The 
role of CysLT1 receptor is also supported by the observation 
that CysLT1 receptor antagonists, pranlukast (ONO-1078) 
and montelukast, protected against acute and chronic 
ischemic brain injury in rats and mice [83-87]. In particular, 
ONO-1078 possessed a neuroprotective effect on global 
cerebral ischemia in rats, at least in part related to the inhibi-
tion of the up-regulation of vascular cell adhesion molecule 1 
(VCAM-1) in different regions of the brain [84].  
 Supporting evidences have been also reported for CysLT2 
receptor [88]. In fact, the expression of CysLT2 receptor 
mRNA was increased in the rat ischemic core at 6, 12 and 24 
h after reperfusion, whereas in the boundary zone after 3, 7 
and 14 days, suggesting its involvement in the acute neu-
ronal injury and late astrocyte proliferation in the ischemic 
brain [88]. The prominent role of CysLT2 in respect to 
CysLT1 receptor has been proved by the use of neuronal cell 
line PC12 [89]. In fact, it has been recently demonstrated 
that transfection with CysLT2, and not with CysLT1 receptor, 
increased OGD-induced PC12 cell death that was attenuated 
by the dual CysLT1/CysLT2 receptor antagonist, BAY u9773 
[90], suggesting a role of this receptor subtype in ischemic 
astrocyte and neural cell death [77].  
 As reported above, recently it has been recently identified 
a new receptor for CysLTs: GPR17 [31]. This receptor (rat 
and human) is expressed in the organs typically undergoing 
ischemic damage, such as brain, heart and kidney. In particu-
lar ischemic damage in a rat focal ischemia model was at-
tenuated by inhibition of GPR17, through either CysLT/P2Y 
receptor antagonists or antisense technology. These results 
suggest an important role of GPR17 in cerebral I/R [31]. 
 In conclusion, though, in an animal model of focal cere-
bral ischemia, no difference in cerebral infarct size has been 
found between 5-LOKO and wild type mice [91], the overall 
results support the view that LTs are involved in the cerebral 
I/R injury. 
2.3. Leukotrienes and Cardiac I/R Injury 
 A number of different pathogenetic events may lead to 
ischemic cardiovascular diseases (ICD), including athero-
sclerosis, small vessel diseases, cardiac arrhythmias and hy-
percoagulation. In turn, these conditions are also dependent 
on a variety of different underlying conditions some of 
which are inherited whereas others are due to exogenous 
factors [92]. Most of the treatments available for ischemic 
insults, including myocardial infarction (MI) and angina, are 
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directed toward preventing the tissue damage inflicted at the 
time of reperfusion, when the coronary flow is restored by 
removing the occlusion. As reported above, genetic factors 
may contribute to the risk of I/R and recently, gene variants 
that predispose patients to MI have been reported [6]. In par-
ticular, variants of gene involved in LT biosynthesis confer 
ethnic specific risk of MI. In fact, a haplotype spanning 
ALOX5AP (FLAP), HapA, was shown to confer risk of both 
MI and stroke in Iceland [6]. On the contrary this ALOX5AP 
variant did not associate to ICD in Sweden [93]. Another 
gene variant in the LT pathway, LTA4 hydrolase, was subse-
quently found to confer increased risk to MI, with an ap-
proximately 3 fold higher risk in African Americans than in 
whites [7]. In particular, measurements of LTB4 production 
suggest that this risk is mediated through upregulation of the 
LT pathway [7]. In fact, it has been demonstrated that, in a 
randomized placebo-controlled phase II trial conducted in 
patients with MI, LTB4 is a risk factor of MI and that inhibi-
tion of FLAP and LT pathway produces suppression of bio-
markers that are associated with MI risk [94]. In contrast, it 
seems that the ALOX5 (5-LO)-promoter polymorphism not 
support variation on MI risk [95]. 
 The role of LTs in I/R of the myocardium is also sup-
ported by the use of inhibitors of their synthesis. In fact, in a 
model of coronary artery ligation in rabbit [96] the treatment 
with BAY X1005, a LT synthesis inhibitor, reduced the mor-
tality rate, protected against the marked electrocardiogram 
derangement and abolished the significant increase in plasma 
creatine kinase activity [96]. Likewise, FLM 5011, a 5-LO 
inhibitor, protected myocardial microvessels against I/R in-
jury after ligation of the left coronary artery in dogs [97]. 
 Other experimental evidences for the involvement of LT 
in myocardial I/R derive from a direct measurement of LT 
levels during episodes of MI. In fact, it has been demon-
strated that LTB4 and cysLT levels in systemic artery blood 
are higher in patients with acute stage of MI and decrease to 
near-normal control levels by one month after the attack 
[98]. Of interest, the urinary excretion of LTE4, the human 
urinary metabolite of cysLTs, was also increased [99]. In 
particular, experimental data suggested that LTC4 is involved 
more in prolonged than in transient MI [100] and that LTD4 
has a negative inotropic and chronotropic effect in isolated 
rat hearts with chronic MI [101]. Thus, the evaluation of 
LTC4 levels might be useful in clinical diagnosis and man-
agement of acute coronary syndromes [102]. Moreover, re-
cently the involvement of the CysLT2 receptor in myocardial 
I/R injury has been highlighted [103]. In fact, endothelium-
targeted over-expression of CysLT2 receptor has been shown 
to aggravate myocardial I/R injury by increasing endothelial 
permeability and by exacerbating inflammatory gene expres-
sion (VCAM-1 and ICAM) [103].  
 The involvement of LTs in acute coronary syndrome is 
also supported by their profound effects on cardiac function, 
which may be mediated through effects on both coronary 
blood flow and cardiac contractility [104]. In fact, the blood 
flow to several vascular beds can be altered by LTs and their 
synthesis and release may play an important role in the regu-
lation of the peripheral circulation [104]. Moreover, LTs, 
besides their action on vascular smooth muscle and myocar-
dium, increase the permeability of blood vessels [104].  
 Although experimental evidence supports a role for LT in 
myocardial I/R, recently it has been suggested, by the use of 
5-LOKO mice, that LTs have no major role in I/R injury in 
the heart [105]. 
2.4. Leukotrienes and Pulmonary I/R Injury 
 Pulmonary I/R injury may result from trauma, atheroscle-
rosis, pulmonary embolism, pulmonary thrombosis and sur-
gical procedures, such as cardiopulmonary bypass and lung 
transplantation. In particular, pulmonary I/R injury occurs in 
up to 22% of patients after lung transplantation and is still 
the main cause of death during the first month after surgery 
[106]. 
 After pulmonary I/R, cellular injury is accompanied by a 
rapid remodelling of membrane lipids with the generation of 
bioactive lipids, such as LTs, that can serve as intra- and/or 
extracellular mediators. The pivotal role of LTB4 in the pul-
monary I/R injury has been valued by several experimental 
data. In particular, neutrophil accumulation in the lung has 
been associated with pulmonary I/R that leads to respiratory 
failure [107, 108]. It has been suggested that the inflamma-
tory cell accumulation was caused by LTB4 generated by the 
ischemic tissue and released into the circulation [109]. In 
fact, LTs mediate neutrophil sequestration and lung edema 
after hindlimb ischemia [109]. Moreover, it has been re-
ported that the leukocytes from transgenic mice, overex-
pressing the LTB4 receptor, showed an increased PMN traf-
ficking to lungs after I/R [110], whereas 5-LOKO mice 
showed lower PMN infiltration in reperfused lungs in com-
parison to 5-LOWT mice [110]. An increase of LTB4 levels 
in bronchoalveolar lavage fluid after I/R injury has also been 
observed in rat I/R lung injury model, [111, 112], as well as 
in serum after pulmonary I/R injury in dogs [113]. Moreover, 
the role of LTs is suggested by reports showing that after 
limb ischemia-induced lung injury [114] there is an increase 
in LTB4 plasma levels as well as in LTC4 blood and bron-
choalveolar lavage fluid level [115].  
2.5. Leukotrienes and Renal I/R Injury 
 Clinically, renal I/R occurs in a variety of medical and 
surgical settings and is responsible for the development of 
ischemic acute renal failure and acute tubular necrosis, e.g. 
in renal transplantation where I/R of the kidney directly in-
fluences graft and patient survival. Multifactorial processes 
are involved in the development and progression of renal I/R 
injury, among them, renal inflammation, involving cyto-
kine/adhesion molecule cascades, with recruitment, activa-
tion, and diapedesis of circulating leukocytes, and chemotac-
tic mediators [116], such as chemokines and 5-LO metabo-
lites [117, 118].  
 The involvement of LT in renal I/R has been demon-
strated by the use of the 5-LO inhibitor, zileuton, which re-
duced renal dysfunction and injury caused by bilateral occlu-
sion and reperfusion of mouse kidneys [119]. The compound 
also abolished the significant increase in plasma levels of 
LTB4 observed in wild-type mice after the bilateral renal I/R. 
Moreover, the degree of renal dysfunction, injury and in-
flammation was reduced in 5-LOKO mice further supporting 
that 5-LO and its metabolites contribute to the pathophysiol-
ogy of renal I/R injury. In particular, both in mice treated 
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with zileuton and in the corresponding 5-LOKO we ob-
served, after I/R, a reduced expression of ICAM-1 in the 
kidney that corresponded to a diminished PMN accumula-
tion. This is not entirely surprising given that the 5-LO me-
tabolite, LTB4, is a potent chemokine. Similar results dem-
onstrated that LTB4 alone appears sufficient to cause cells to 
migrate into post ischemic renal tissue supporting the role for 
this LT as an important mediator in the pathophysiology of 
renal dysfunction caused by kidney I/R [120].  
 The role of cysLTs in renal I/R has been also investigated 
by the use of receptor antagonists [121]. It has been demon-
strated that CysLT1 receptor antagonist, montelukast, re-
versed I/R-induced oxidant responses and improved micro-
scopic damage and renal function. It seems likely that mon-
telukast protects kidney tissue by inhibiting neutrophil infil-
tration, balancing oxidant-antioxidant status and regulating 
the generation of inflammatory mediators [121].  
2.6. Leukotrienes and Intestinal I/R Injury 
 Intestinal I/R injury is generally the result of arterial oc-
clusion by thrombi or emboli and, more frequently, by non 
occlusive processes, like acute mesenteric ischemia, small 
bowel transplantation, abdominal aortic aneurysm, severe 
burns and hemorrhagic, traumatic or septic shock [122]. I/R 
injury of the gastrointestinal tract, associated with haemor-
rhage and other shock states, is characterized by a number of 
microvascular and mucosal alterations, including endothelial 
cell swelling, capillary plugging, a prolonged reduction in 
gastrointestinal blood flow and mucosal barrier dysfunction 
[123]. An important component of intestinal I/R is endothe-
lial dysfunction [124, 125] especially attributed to activated 
adherent PMNs [126]. In fact, I/R is a stimulus for leuko-
cyte-endothelial cell interaction and migration into tissues.  
 It has been demonstrated that LTB4 plays a pivotal role in 
endothelial dysfunction occurring in splanchnic artery occlu-
sion shock (SAO), in the rats, by chemoattraction and activa-
tion of neutrophils on the surface of vascular endothelial 
cells [127]. Moreover, it seems that the activation of BLT 
receptor plays a minor role in the local, remote and systemic 
injuries following severe intestinal I/R in rats [128]. The role 
of 5-LO metabolites has been also investigated by the use of 
5-LOKO mice. In fact, we have demonstrated that 5-LO me-
diates leukocyte-endothelial cell interactions by regulating 
the expression of P-selectin, E-selectin and ICAM-1 during 
SAO in 5-LOKO animals [58]. Interestingly, the down-
regulation of the adhesion molecules, in the intestine as well 
as in the lung tissue of SAO-shocked 5-LOKO mice, was 
associated with the reduction of leukocyte infiltration.  
 The role of LTs is also supported by results demonstrat-
ing that LTB4 and LTC4 levels triple after I/R in the canine 
intestinal mucosa [129] and that LTC4 regulates the splanch-
nic blood flow during mild haemorrhage/reperfusion injury 
in rats [130]. More generally, LTs seem to play a significant 
role also in other experimental models of I/R intestinal in-
jury, like in a canine model of hypothermic I/R injury [131] 
and in hypotension associated with I/R of the small intestine 
in rats [132]. In particular, in this model the inhibition of LT 
biosynthesis by zileuton significantly improved
 
reperfusion, 
intestinal blood flow and VO2, and abolishes the I/R-induced
 
increase in mucosal neutrophil infiltration in normothermic 
I/R
 
injury [129].  
 Recently, it has been demonstrated that splanchnic I/R in 
rats activates gut PLA2-mediated release of AA into the 
lymph where it is delivered to the lungs, provoking LTB4 
production and subsequent PMN-mediated lung injury [133].  
2.7. Leukotrienes and Hepatic I/R Injury 
 Hepatic injury secondary to I/R is an important clinical 
issue. It has been implicated in the pathogenesis of a variety 
of clinical conditions including trauma, thermal injury, hy-
povolemic and endotoxin shock, reconstructive vascular sur-
gery, liver transplantation and liver resection surgery [134-
139]. Possible consequences of hepatic I/R injury include 
liver failure and/or multi-organ system failure, resulting in 
morbidity and mortality [140]. Extensive investigations dur-
ing the past decade suggest that an inflammatory response 
and microcirculatory disturbances contribute to reperfusion 
injury and cause, in severe cases, liver failure [139, 141, 
142]. It has been reported that LTs are associated with sev-
eral liver injury such as fulminant hepatitis [143], liver cir-
rhosis [144], cholestasis, hepatic inflammation, portal hyper-
tension, hepatorenal syndrome, fulminant hepatic failure, 
primary graft nonfunction following liver transplantation 
[145, 146] and hepatic I/R injury [147]. In particular, a 4- to 
5-fold increase of the cysLTs content in the hepatic tissue 
after 12 and 24 h reperfusion, accompanied by the enhance-
ment of hepatic edema and plasma ALT elevation, has been 
observed [148]. According to recent findings LTC4 accumu-
lation in rat liver subjected to I/R may be partially caused by 
up-regulation of LTC4S expression and by the increase of 
LTC4 synthesis enzyme and/or activities [149]. However, 
since the pathophysiology of hepatic I/R injury is so compli-
cated, it is essential to further study the mechanisms respon-
sible for LTC4 accumulation in hepatic I/R injured rats [149].  
 Contrasting data have been reported on LTB4 involve-
ment in hepatic I/R injury. In fact, either an increase or no 
change in LTB4 levels have been observed after hepatic I/R 
injury [150]. Therefore, the involvement of LTB4 needs fur-
ther investigations. 
3. INVOLVEMENT OF LEUKOTRIENES IN THE 
PATHOGENESIS OF SHOCK 
3.1. Shock 
 Sepsis is a complex pathophysiological response of the 
body to a systemic infection and may result in severe disor-
ders such as septic shock, characterized by hypotension, hy-
pothermia, poor tissue perfusion and multi organ dysfunction 
syndrome (MODS) [151, 152]. In particular, severe sepsis is 
defined as the presence of sepsis and one or more organ dys-
functions (acute lung injury; coagulation abnormalities; 
thrombocytopenia; altered mental status; renal, liver, or car-
diac failure; hypoperfusion with lactic acidosis) [153, 154], 
while septic shock is defined as the presence of sepsis and 
arterial hypotension [155]. The mortality rate of sepsis may 
range from 30% to 50% for severe cases [156].  
 The inflammatory response is a central component of 
sepsis as it drives the physiological alterations that are rec-
ognized as the systemic inflammatory response syndrome 
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(SIRS) [157]. A successful inflammatory response eliminates 
the invading microorganisms without causing lasting dam-
age, however sepsis develops when the initial appropriate 
host response to an infection becomes amplified and then 
aberrant. Many scientists believe that sepsis develops as a 
result of production of several mediators such as pro-
inflammatory molecules (TNF-, IL-1, IL-6 and IL-8), 
lysosomal enzymes, superoxide-derived free radicals, 
vasoactive substances and eicosanoids [prostaglandins (PGs) 
and LTs] [158]. Moreover, the vascular changes in septic 
shock [159] have been interpreted on the basis of the effects 
of inflammatory mediators on the vascular endothelium 
[160]. In fact, the initial responses to endotoxemia are de-
tectable in the microcirculation as a microvascular inflamma-
tory response characterized by activation of the endothelium 
stimulating these cells from their normal anticoagulant state 
to a procoagulant state with increased adhesiveness for plate-
lets and leukocytes. The infiltration and accumulation of 
PMNs represent a crucial event for the development of sec-
ondary organ and tissue damage [161-164]. Moreover, leu-
kocyte/endothelial cell interaction is also induced by the 
generation of pro-inflammatory mediators, such as LTs, 
which up-regulate adhesion molecule expression [165-167]. 
It has therefore been proposed that during human sepsis a 
widespread endothelial damage and death occurs which leads 
to MODS. 
3.2. Leukotrienes and Septic and Non Septic Shock 
 LT generation in sepsis may serve as a biomarker for 
survival in the critical ill [168] since a negative correlation 
between the ability of blood mononuclear cells to synthesize 
LTC4 and mortality in septic patients has been identified. In 
fact, a significantly increased mortality rate has been ob-
served [169] in septic patients, whose in vitro stimulated 
pooled blood mononuclear cells were unable to produce in-
creased amount of LTC4 over time. Moreover, [170], it has 
been reported that in sepsis the PG basal levels in white 
blood cells (WBC) were significantly decreased in compari-
son to healthy subjects, whereas isolated WBC stimulated 
with AA have the same capacity to generate PG. In contrast, 
LT levels were significantly higher in septic patients than in 
healthy subjects, but WBC were able to produce, after stimu-
lation with AA, greater amount of LTs only in patients who 
survived the septic state. The authors suggested that this in-
ability of WBC to further enhance LT production during the 
course of sepsis in non-survivors could be explained as part 
of the “immunoparalysis” seen during sepsis associated with 
bad outcome. Thus, the functional analysis of LTs and PGs 
during sepsis might turn out to be a suitable approach for the 
estimation of the future course of the disease [170].  
 Moreover, a complex dynamic equilibrium between PGs 
and LTs in septic shock has been suggested. In fact, PGI2 
blockade during bacteraemia significantly increased LT pro-
duction that on the contrary was decreased by PGI2 infusion, 
suggesting that endogenous PGI2 may blunt LT release dur-
ing septic shock [171]. These data indicate that LT produc-
tion can also be regulated by PGs.  
 The immunopathogenesis of sepsis is characterized by an 
overwhelming suppressed adaptive immunity [172, 173]. 
Although activation of the innate immune system by micro-
bial pathogens and their products was reported to contribute 
to hyper-inflammation and organ injury during systemic in-
flammatory responses, many aspects of sepsis immunopa-
thogenesis need further elucidation.  
 The overall results concerning the role of LTs in the im-
mune response demonstrate that they have divergent effects 
during the induction and evolution of septic shock. Initially, 
they participate in local innate immune control. However, if 
the severity of infection overwhelms local immunity and 
microbial dissemination ensues, cysLTs contribute to the 
deleterious effects on the vasculature, resulting in vascular 
leak, hypotension and inadequate tissue perfusion [174]. In 
fact, a reduction in peritoneal neutrophil accumulation and 
an increase in the number of bacteria in the peritoneal cavity 
has been demonstrated, in different models of peritonitis 
with severe sepsis (such as a cecal ligation and puncture), in 
5-LOKO mice. Despite this impairment of local innate im-
munity, the null mice exhibited a marked improvement in 
survival, and this protection was also seen in wild-type ani-
mals treated with the LT synthesis inhibitor, MK 886. A sur-
vival advantage in severe sepsis was also observed in mice 
treated with the CysLT receptor antagonist, MK 571, but not 
with the LTB4 receptor antagonist, CP 105 [174]. Moreover, 
in the 5-LOKO mice a reduced vascular leak and serum lac-
tate levels was observed, whereas treatment of wild-type 
mice with MK 571 produced a less sepsis-induced hypoten-
sion [174]. These data demonstrate opposite effects of 
cysLTs on innate immune vs hemodynamic responses, dem-
onstrating protective effects on local immunity and deleteri-
ous effects on the vasculature [174]. In particular, cysLTs 
have long been recognized to increase microvascular perme-
ability in various organs [175-178]. Thus, although LTs ini-
tially play a protective role during septic shock development, 
they play a detrimental role, indicating salutary effects of LT 
inhibitors and antagonists in endotoxin shock [179]  
 Septic shock induced by the injection of endotoxin is 
widely used in animal experimental models, and hypother-
mia is one of the prominent features of the acute phase re-
sponse to lipopolysaccharide (LPS) [180]. It has been dem-
onstrated that MK 886 significantly attenuated the hypo-
thermia induced by LPS and significantly reduced the eleva-
tion in hypothalamic LT production in the rats [180]. 
Moreover, in a model of rat endotoxic shock, the treatment 
with BW A137C, a 5-LO inhibitor, attenuated acute mi-
crovascular injury produced by LPS [181]. Similarly, the 
administration of MK 886 attenuated the hypotension and 
partially reversed the impaired vascular responsiveness ob-
served in a rabbit model of endotoxic shock [182] as well as 
blocked the toxin-induced coronary vasoconstrictor response 
and the loss of rat myocardial contractility [183]. Thus, the 
overall results show that LTs cause pulmonary hypertension, 
systemic hypotension [184], hypothermia [185] and an in-
creased vascular permeability during bacteraemia [184]. 
 As previously reported, septic shock can develop into 
MODS, with lung as the first organ involved. In particular, 
LTs have been implicated as possible mediators of endo-
toxin-induced acute lung injury. In fact, the presence of LTs 
in the bronchoalveolar lavage fluid of patients with sepsis as 
well as an increase of cysLT levels in lung tissue of endo-
toxin-challenged rodents, has been reported [186, 187]. 
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Moreover infusion of LTs into animals produced an acute 
lung injury resembling the clinical presentation of endo-
toxemia, which includes pulmonary hypertension and in-
creased vascular permeability, resulting in pulmonary oe-
dema and hypoxemia [188, 189].  
 Another target organ during sepsis is the liver, which is 
continuously exposed to endotoxin via the portal circulation. 
Liver sinusoidal cells, in particular macrophages and endo-
thelial cells play an important role in clearance of endotoxin 
from the blood [190]. Excessive levels of endotoxin can 
readily overcome this clearance mechanism leading to liver 
damage [191]. The release of oxidants eicosanoids and cyto-
toxic pro-inflammatory cytokines by LPS-activated macro-
phages and endothelial cells seems to be in part implicated in 
this process [192-194]. In fact, it has been demonstrated that 
5-LO mRNA expression is increased after endotoxin admini-
stration in liver endothelial cells providing additional support 
for the idea that LTs play a role in recruitment and activation 
of leukocytes into liver tissue during acute endotoxemia 
[195]. Moreover, we have demonstrated in collaboration 
with Thiemermann and coworkers [56], that lung, liver, il-
eum, renal and pancreatic dysfunction and injury, caused by 
endotoxemia, as well as PMN infiltration in the lung and 
ileum, were reduced in rats treated with 5-LO inhibitor zileu-
ton and in 5-LOKO mice. Zileuton also reduced the LPS-
induced expression of 2 integrins CD11b/CD18 on rat leu-
kocytes. Thus zileuton seems to protect organs against endo-
toxin-induced dysfunction and injury by inhibiting the LT 
synthesis, thereby reducing the LT-induced stimulation of 
2-integrin-dependent adhesion and the subsequent recruit-
ment of neutrophils [56].  
 It is known that MODS remains a principal cause of 
death after severe shock or trauma, not only in the presence, 
but also in the absence of sepsis [196-202]. A marked bio-
synthesis of LTC4 and LTB4 was observed also in an experi-
mental model of MODS induced by non septic shock (zymo-
san-induced peritonitis and MODS) [203]. Other results sup-
port the pivotal role of LTs in zymosan-induced peritonitis 
model. In fact, oedema associated with zymosan-induced 
peritonitis was markedly reduced in animals lacking FLAP 
[204] and it has been reported that 5-LO inhibitors and LTB4 
receptor antagonists are effective in preventing the develop-
ment of organ failure since they reduce neutrophil infiltration 
[203]. Same results were obtained by the use of LTA4 hydro-
lase-deficient mice [205] and 5LOKO mice [57]. Interest-
ingly, a reduced expression of adhesion molecules, such as 
P-selectin and ICAM-1 in the lung and ileum was observed. 
Thus, as for septic shock, these results demonstrate that LTs 
exert a role in zymosan-induced non septic shock by the 
regulation of neutrophil recruitment both at the rolling and 
firm adhesion phase [57].  
 Similar data were obtained in another model of non sep-
tic induced-MODS [206]. In fact, it has been demonstrated 
that chronic renal failure-induced multiple-organ injury in 
rats is alleviated by the selective CysLT1 receptor antagonist 
montelukast [206]. In particular, protective effects of monte-
lukast on chronic renal failure-induced injury were attributed 
to its ability to inhibit neutrophil infiltration and apoptosis, to 
balance oxidant-antioxidant status and to regulate the genera-
tion of pro-inflammatory mediators [206]. Moreover, it has 
been observed an increase in pulmonary LTB4 production 
within the lung also in an experimental model of traumatic 
brain injury that is known to cause several secondary effects, 
which lead to MODS [207].  
4. SUMMARY 
 This review discusses the role of LT pathway in various 
forms of I/R injury (cerebral, cardiac, pulmonary, renal, in-








 
Fig. (1). Proposed scheme for the role of LT pathway in I/R injury and shock. 
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testinal and hepatic) and shock (septic and non septic), and 
delineates the evidence supporting the potential beneficial 
utility of anti-LT therapy (5-LO inhibitors and LT receptor 
antagonists) as a promising new approach to limit I/R-and 
shock-induced tissue damage. 
 There is a marked activation of LT biosynthetic pathway 
in various forms of I/R and shock, which correlates with the 
degree of tissue injury and inflammation. In particular, ac-
cumulating evidences suggest that anti-LT therapy may pro-
tect against organ I/R injury by decreasing the endothelial 
cell activation/inflammatory response, vascular permeability 
and recruitment, adhesion and activation of inflammatory 
cells by the inhibition of the adhesion molecule expression 
(Fig. (1)).  
 A better understanding of the mechanisms underlying the 
role of the 5-LO enzyme and/or its metabolites, in particular 
LTs, in the regulation of neutrophil trafficking, might open 
new perspectives in the treatment of organ damage associ-
ated with shock and I/R injury.  
ABBREVIATIONS 
5-HPETE = 5-Hydroperoxyeicosatetraenoic acid 
5-HETE = 5-Hydroxyeicosatetraenoic acid 
5-LO = 5-Lipoxygenase 
FLAP = 5-Lipoxygenase-activating protein 
AA = Arachidonic acid 
cysLT = Cysteinyl LT 
cPLA2 = Cytosolic phospholipase A2 
CLP = Coactosin-like protein 
ERK = Extracellular signal-regulated kinase 
GPR17 = G protein–coupled receptor 17 
I/R = Ischemia and reperfusion 
ICD = Ischemic cardiovascular diseases 
KO = Knockout 
LTs = Leukotrienes 
LTB4 = Leukotriene B4 
LTC4S = Leukotriene C4 (LTC4) synthase 
LTD4 = Leukotriene D4 
LTE4 = Leukotriene E4 
LPS = Lipopolysaccharide 
MAPK = Mitogen-activated protein kinase 
MODS = Multi organ dysfunction syndrome 
MI = Myocardial infarction 
PMNs = Polymorphonuclear leukocytes 
PGs = Prostaglandins 
SAO = Splanchnic artery occlusion shock 
SIRS = Systemic inflammatory response syndrome 
VCAM-1 = Vascular cell adhesion molecule 1 
WBC. = White blood cells 
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